Brii Biosciences Announces Upcoming Participation at November Conferences
Oct 14, 2021

DURHAM, N.C., United States and BEIJING, China – October 14, 2021

DURHAM, N.C., United States and BEIJING, China – October 14, 2021 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced its participation in the following conferences in November 2021. Details of the conferences and management participations are as follows:
Goldman Sachs Asia Pacific Healthcare Forum 2021 (Virtual)
One-on-one and small group meetings: November 15-17, 2021
Management participants:
- Dr. Zhi Hong, Co-Founder, Chairman of the Board and Chief Executive Officer
- Mr. Rogers Luo, Executive Director, President and General Manager of Greater China
- Dr. Li Yan, Chief Medical Officer
- Dr. Ankang Li, Chief Financial Officer and Joint Company Secretary
- Ms. Chris Fang, Investor Relations Director
For more information, please contact your Goldman Sachs representative.
Morgan Stanley Twentieth Annual Asia Pacific Summit (Virtual)
One-on-one and small group meetings: November 17-19, 2021
Management participants:
- Dr. Zhi Hong, Co-Founder, Chairman of the Board and Chief Executive Officer
- Mr. Rogers Luo, Executive Director, President and General Manager of Greater China
- Dr. Li Yan, Chief Medical Officer
- Dr. Ankang Li, Chief Financial Officer and Joint Company Secretary
- Ms. Chris Fang, Investor Relations Director
For more information, please contact your Morgan Stanley representative.
About Brii Bio
Brii Biosciences Limited (“Brii Bio”, or the “Company”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.